These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 29606503)

  • 1. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
    Sonoda H; Morimoto H; Yoden E; Koshimura Y; Kinoshita M; Golovina G; Takagi H; Yamamoto R; Minami K; Mizoguchi A; Tachibana K; Hirato T; Takahashi K
    Mol Ther; 2018 May; 26(5):1366-1374. PubMed ID: 29606503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
    Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
    Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
    Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Drug Metab Dispos; 2012 Feb; 40(2):329-35. PubMed ID: 22065691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO
    Yamamoto R; Kawashima S
    Nihon Yakurigaku Zasshi; 2022; 157(1):62-75. PubMed ID: 34980815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
    Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
    BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
    Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H
    Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
    Giugliani R; Martins AM; Okuyama T; Eto Y; Sakai N; Nakamura K; Morimoto H; Minami K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Schmidt M; Sato Y
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.
    Arguello A; Mahon CS; Calvert MEK; Chan D; Dugas JC; Pizzo ME; Thomsen ER; Chau R; Damo LA; Duque J; Fang M; Giese T; Kim DJ; Liang N; Nguyen HN; Solanoy H; Tsogtbaatar B; Ullman JC; Wang J; Dennis MS; Diaz D; Gunasekaran K; Henne KR; Lewcock JW; Sanchez PE; Troyer MD; Harris JM; Scearce-Levie K; Shan L; Watts RJ; Thorne RG; Henry AG; Kariolis MS
    J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35226042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
    Okuyama T; Eto Y; Sakai N; Nakamura K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Sato Y
    Mol Ther; 2021 Feb; 29(2):671-679. PubMed ID: 33038326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.
    Lu JZ; Boado RJ; Hui EK; Zhou QH; Pardridge WM
    Biotechnol Bioeng; 2011 Aug; 108(8):1954-64. PubMed ID: 21351076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
    Laoharawee K; DeKelver RC; Podetz-Pedersen KM; Rohde M; Sproul S; Nguyen HO; Nguyen T; St Martin SJ; Ou L; Tom S; Radeke R; Meyer KE; Holmes MC; Whitley CB; Wechsler T; McIvor RS
    Mol Ther; 2018 Apr; 26(4):1127-1136. PubMed ID: 29580682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
    Imakiire A; Morimoto H; Suzuki H; Masuda T; Yoden E; Inoue A; Morioka H; Konaka T; Mori A; Shirasaka R; Kato R; Hirato T; Sonoda H; Minami K
    Mol Pharm; 2023 Nov; 20(11):5901-5909. PubMed ID: 37860991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
    Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
    Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.